A recent study at Tel Aviv University in Israel, tested 60 volunteers using a brain exercising computer program, MindFit, for 30 minutes, three times a week, and compared them with another 60 playing sophisticated computer games.

The results showed that although all benefited from playing on the computer, those on MindFit had better improvement in short-term learning, visual and spatial learning and focused attention.

These findings are especially relevant to those of a certain age and show that exercise can stave off the reduction of mental faculties. It seems that very few golden agers realize that giving the brain a workout is just as important as physical exercise.

Susan Greenfield, a neurologist and Director of the Royal Institution, is supporting the use of computer brain games to tackle mental decline.

She believes that with no cure for Alzheimer’s disease on the horizon, these exercises are a good way of staving off dementia and keeping the mind alert.

Baronness Greenfield will launch MindFit in the House of Lords in October. She says, “There is now good scientific evidence to show that exercising the brain can slow, delay and protect against age related decline”.

Nintendo, the computer console company, is behind another product, the Brain Training computer game. The Brain-Master keeps the mind agile by testing logical analysis, memory retention, coordination and concentration.

The developer of the software, Professor Ryuta Hawashima of Japan’s Tohonu University, said the games increase the delivery of oxygen, blood and amino acids to the brain, leading to the creation of connections between brain cells.

MindFit is a new rival, developed in Israel and already available in the U.S. Baroness Greenfield is involved with the company producing the software and her name will be used to promote it in Britain, where it will cost £70 ($140).

The software claims to improve short-term memory by 18 percent, eye-hand co-ordination by 16.5 percent, memory recall by 14 percent and reaction time by 12.5 percent.

A new study found that injection of the protein Granulocyte-Colony Stimulating Factor (G-CSF) following stroke reduces the area affected by a third, even when injected 3 days after the stroke.

G-CSF regulates apotosis (programmed cell death) and neurogenesis (the creation of new neurons). The study found that G-CSF injected within four hours of a stroke reduced the size of the infarct and regular, delayed injections were effective in restoring motor functions in rats.

These data further strengthen G-CSF’s profile as a unique candidate stroke drug, and provide an experimental basis for application of G-CSF in the post-stroke recovery
phase.

BioMed Central Abstract - G-CSF treatment in cerebral ischemia